Asahi Kasei has completed the construction of its second plant for Ceolus microcrystalline cellulose (MCC) at its Mizushima Works in Kurashiki, Okayama, Japan.
Completed in January 2023, the new facility underlines the company's commitment to meet the substantially growing demand for its MCC.
The Functional Additives Division of Asahi Kasei’s Life Innovation SBU has manufactured Ceolus in Nobeoka, Miyazaki, Japan, since 1970. Ceolus is supplied to customers around the world, primarily for use as a tablet binder for pharmaceuticals.
Demand for Ceolus used in pharmaceutical tablets is growing substantially, especially for the proprietary high-performance grades Ceolus KG and Ceolus UF. The second plant will not only raise supply capacity but also enhance supply stability through production at multiple sites. The new plant is currently undergoing trial operation, with commercial production of each grade scheduled to begin in succession from April 2023.
The increased capacity at this new plant will enable us to provide a more stable supply of Ceolus for distribution centres around the world to get products to customers in greater quantities
- Eiichi Hori, Senior General Manager of the Functional Additives Division
“The increased capacity at this new plant will enable us to provide a more stable supply of Ceolus for distribution centres around the world to get products to customers in greater quantities,” said Eiichi Hori, Senior General Manager of the Functional Additives Division. “The second plant will make Ceolus more accessible to patients around the world. We are excited to see the innovative, new formulations that pharmaceutical and supplement manufacturers will develop utilising our MCC.”
Featuring an innovative particle morphology, Ceolus offers various solutions to the pharmaceutical and supplement industries: It facilitates challenging formulations, solves tabletting issues, and enables unique and patient-friendly dosage forms. It also contributes to customers’ production efficiency by enabling high-speed tabletting and reducing production problems. In addition, fewer black particles, fewer impurities including nitrite and nitrate, which may cause nitrosamine associated risk, and the consistently high quality of Ceolus directly contribute to the quality improvement of customers’ formulations.
Asahi Kasei expects that the new plant will make a further contribution to life and living for people around the world by providing Ceolus to more customers globally, enabling the manufacture of pharmaceuticals and supplements that have been difficult to make into tablets, and meeting the needs of pharmaceutical companies, supplement companies, and patients through the development of high-performance products.
